A single-center, open-label investigator-sponsored phase I study for propranolol/etodolac in combination with nanoparticle albumin-bound-paclitaxel and gemcitabine in metastatic pancreatic cancer patients

Trial Profile

A single-center, open-label investigator-sponsored phase I study for propranolol/etodolac in combination with nanoparticle albumin-bound-paclitaxel and gemcitabine in metastatic pancreatic cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2015

At a glance

  • Drugs Propranolol/etodolac (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2015 New trial record
    • 16 Jan 2015 Results were presented at the 2015 Gastrointestinal Cancers Symposium, according to a Vicus Therapeutics media release.
    • 16 Jan 2015 Results published in a Vicus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top